Clonidine-displacing substance and its putative role in control of insulin secretion: A minireview

General Pharmacology

Volumn 31, Issue 4, 1998, Pages 525-529

  Chan, Susan L F ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

Agmatine; CDS; Endocrine pancreas; Endogenous ligand; I site; Imidazoline; Insulin secretion

Indexed keywords

2 (2,3 DIHYDRO 2 BENZOFURANYL) 2 IMIDAZOLINE; AGMATINE; DIAZOXIDE; EFAROXAN; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE RECEPTOR; KU 14R; UNCLASSIFIED DRUG;

BINDING SITE; CATTLE; CONTROLLED STUDY; INSULIN RELEASE; NONHUMAN; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

AGMATINE; ANIMALS; BINDING SITES; CELLS, CULTURED; CLONIDINE; HUMANS; IMIDAZOLES; INSULIN; ISLETS OF LANGERHANS;

EID: 0032189154     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(98)00052-4     Document Type: Review

References (53)

1. Alberti K.G.M.M., Woods H.F., Whalley M.D. Mechanism of action of the monoguanidine hypoglycaemic agents, galegine and agmatine. Eur. J. Clin. Invest. 3:1973;208.
2. Atlas D. Clonidine-displacing substance (CDS) and its putative imidazoline receptor. Biochem. Pharmac. 41:1991;1541-1549.
3. Atlas D. Molecular and physiological properties of clonidine-displacing substance. Ann. N. Y. Acad. Sci. 763:1995;314-324.
4. Atlas D., Burstein Y. Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS. Lett. 170:1984;387-390.
5. Bennai F., Greney H., Bricca G., Belcourt A., Bousquet P., Dontenwill M. Polyclonal anti-idazoxan antibodies. characteriaztion and purification Eur. J. Pharmac. 246:1993;45-51.
6. Berdeu D., Puech R., Loubatieres-Marini M.-M., Bertrand G. Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed. Eur. J. Pharmac. 308:1996;301-304.
7. Bousquet P., Feldman J., Atlas D. An endogenous non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur. J. Pharmac. 124:1986;167-170.
8. Brown C.A., Chan S.L.F., Stillings M.R., Smith S.A., Morgan N.G. Antagonism of the stimulatory effects of efaroxan and glibenclamide in rat pancreatic islets by the imidazoline RX801080. Br. J. Pharmac. 110:1993;1017-1022.
9. 2-adrenoceptors and imidazoline binding sites in control of insulin secretion. Clin. Sci. 85:1993;671-677.
10. Chan S.L.F., Morgan N.G. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur. J. Pharmac. 176:1990;97-101.
11. 2-adrenoceptor antagonist, efaroxan, involves a novel stereoselective binding site. Eur. J. Pharmac. 230:1993;375-378.
12. 2-sites Br. J. Pharmac. 112:1994;1065-1070.
13. Chan S.L.F., Cable H.C., Morgan N.G. Agmatine, a putative endogenous ligand at imidazoline binding sites, is a weak potentiator of insulin secretion. Pharmac. Commun. 7:1995;29-41.
14. Chan S.L.F., Atlas D., James R.F.L., Morgan N.G. The effect of the putative endogenous imidazoline receptor ligand, clonidine-displacing substance, on insulin secretion from rat and human islets of Langerhans. Br. J. Pharmac. 120:1997;926-932. a.
15. Chan S.L.F., Pallett A.L., Clews J., Ramsden C.A., Morgan N.G. Evidence that the ability of imidazoline compounds to stimulate insulin secretion is not due to interaction with σ receptors. Eur. J. Pharmac. 323:1997;241-244. b.
16. Diamant S., Atlas D. An endogenous ligand substance, CDS (clonidine-displacing substance), inhibits the twitch response of rat vas deferens. Biochem. Biophys. Res. Commun. 134:1986;184-190.
17. 2-adrenoceptors of human platelets. Eur. J. Pharmac. 144:1987;247-255.
18. Dontenwill M., Bricca G., Molines A., Bousquet P., Belcourt A. Production and characterization of anti-clonidine antibodies not cross-reacting with catecholamines. Eur. J. Pharmac. 149:1988;249-255.
19. Dontenwill M., Molines A., Verdin A., Bricca G., Laurent S., Bousquet P. A circulating substance cross-reacting antiimidazoline antibodies. detection in serum in relation to essential hypertension J. Clin. Invest. 92:1993;1068-1072.
20. Dunne M.J. Block of ATP-regulated potassium channels by phentolamine and other α-adrenoceptor antagonists. Br. J. Pharmac. 103:1991;1847-1850.
21. Felsen D., Ernsberger P., Meeley M.P., Reis D.J. Clonidine-displacing substance is biologically active on smooth muscle. Eur. J. Pharmac. 142:1987;453-455.
22. Frank E., Nothmann M., Wagner A. Synthetic compounds having an insulin-like activity in the normal and in the diabetic organism. Klin. Wochenschr. 5:1926;2100-2107.
23. Goldberg-Stern H., Atlas D., Schwartz I., Achiron A., Ziv I., Djaldetti R., Zoldan Y., Melamed E. Measurement of an endogenous clonidine-displacing substance in human cerebrospinal fluid. Brain Res. 601:1993;325-328.
24. Hensley M.L., Meeley M.P., McCauley P.M., Ernsberger P., Reis D.J. Clonidine-displacing substance is present in peripheral tissues of the rat. Am. J. Hypertens. 2:1989;917-919.
25. + channels and insulinotropic action by the antiarrhythmic agent, cibenzoline. Br. J. Pharmac. 117:1996;1749-1755.
26. Kalra S.P., Pearson E., Sahu A., Kalra P.S. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Neurosci. Lett. 194:1995;165-168.
27. Le Brigand L., Virsolvy A., Peyrollier K., Manechez D., Godfroid G.-G., Guardiola-Lemaitre B., Bataille D. Stimulation of insulin release from MIN6 cell line by a new imidazoline compound, S-21663. evidence for the existence of a novel imidazoline site in β-cells Br. J. Pharmac. 122:1997;786-791.
28. Li G., Regunathan S., Barrow C.J., Esharghi J., Cooper R., Reis D.J. Agmatine is an endogenous clonidine-displacing substance in brain. Science. 263:1994;966-969.
29. Meeley M.P., Ernsberger P.R., Granata A.R., Reis D.J. An endogenous clonidine-displacing substance from bovine brain. receptor binding and hypotensive actions in the ventrolateral medulla Life Sci. 38:1986;1119-1126.
30. Meeley M.P., Hensley M.L., Ernsberger P., Felsen D., Ernsberger D.J. Evidence for a bioactive clonidine-displacing substance in peripheral tissues and serum. Biochem. Pharmac. 44:1992;733-740.
31. Michel M.C., Ernsberger P. Keeping an eye on the I-site. imidazoline-preferring receptors Trends Pharmac. Sci. 13:1992;369-370.
32. Molderings M. Imidazoline receptors. basic knowledge, recent advances and future prospects for therapy and diagnosis Drugs Future. 22:1997;757-772.
33. Morgan N.G., Chan S.L.F., Brown C.A., Tsoli E. Characterization of the imidazoline binding site involved in regulation of insulin secretion. Ann. N. Y. Acad. Sci. 763:1995;361-373.
34. 2 receptors. Eur. J. Pharmac. 262:1994;41-48.
35. Parini A., Gargalidis Moudanos C., Pizzinat N., Lanier S.M. The elusive family of imidazoline binding sites. Trends Pharmac. Sci. 17:1996;13-16.
36. Piletz J.E., Chikkala D.N., Ernsberger P. Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha-2 adrenergic receptors. J. Pharmac. Exp. Ther. 272:1995;581-587.
37. 2-adrenoceptors which modulate the firing rate of locus coeruleus neurones. an electrophysiological study in rat Neurosci. Lett. 219:1996;103-106.
38. 2-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmac. 351:1995;10-16.
39. + channels in mouse pancreatic β-cells. Br. J. Pharmac. 101:1990;115-120.
40. Raasch W., Regunathan S., Li G., Reis D.J. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci. 56:1995;2319-2330.
41. Regunathan S., Reis D.J. Imidazoline receptors and their endogenous ligands. Annu. Rev. Pharmac. Toxicol. 36:1996;511-544.
42. Regunathan S., Meeley M.P., Reis D.J. Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells. Mol. Pharmac. 40:1991;884-888.
43. Reis D.J., Li G., Regunathan S. Endogenous ligands of imidazoline receptors. classic and immunoreactive clonidine-displacing substance and agmatine Ann. N. Y. Acad. Sci. 763:1995;295-313.
44. ATP channels in pancreatic B-cells. Naunyn-Schmiedeberg's Arch. Pharmac. 356:1997;410-417.
45. Schulz A., Hasselblatt A. An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmac. 340:1989;321-327.
46. Sener A., Lebrun P., Blachier F., Malaisse W.J. Stimulus-secretion coupling of arginine-induced insulin release. Biochem. Pharmac. 38:1989;327-330.
47. Singh G., Hussain J.F., Mackinnon A., Brown C.M., Kendall D.A., Wilson V.G. Evidence for the presence of a non-catecholamine, clonidine-displacing substance in crude, methanolic extracts of bovine brain and lung. Naunyn-Schmiedeberg's Arch. Pharmac. 351:1995;17-26.
48. Stickle D., Bohrer A., Berger R., Morrisey J., Klahr S., Turk J. Quantitation of the putative neurotransmitter agmatine as the hexafluroacetylacetone derivative by stable isotope dilution gas chromatography and negative-ion chemical ionization mass spectrophotometry. Anal. Biochem. 238:1996;129-136.
49. Synetos D., Manolopoulos V.G., Atlas D., Pipili-Synetos E. Human plasma-derived material with clonidine-displacing substance (CDS)-like properties contracts the isolated rat aorta. J. Auton. Pharmac. 11:1991;343-351.
50. Virsolvy-Vergine A., Brǔck M., Dufour M., Cauvin A., Lupo B., Bataille D. An endogenous ligand for the central sulfonylurea receptor. FEBS Lett. 242:1988;65-69.
51. Virsolvy-Vergine A., Leray H., Kuroki S., Lupo B., Dufour M., Bataille D. Endosulfine, an endogenous peptidic ligand for the sulfonylurea receptor. purification and partial characterization from ovine brain Proc. Natl. Acad. Sci. USA. 89:1992;6629-6633.
52. Virsolvy-Vergine A., Salazar G., Sillard R., Denoroy L., Mutt V., Bataille D. Endosulfine, endogenous ligand for the sulphonylurea receptor. isolation from porcine brain and partial structural determination of the α form Diabetologia. 39:1996;135-141.
53. ATP channels and interaction with the exocytotic machinery. Diabetes. 45:1996;1610-1618.